Clinical trials: Preventive Treatment of Migraine
Migraine, Migraine With Aura
Effectiveness and Tolerability of Eptinezumab
The purpose of this prospective and multicentric study is to evaluate the effectiveness and tolerability of eptinezumab as preventive migraine treatment in a cohort of episodic or chronic migraine patients.
- Conditions
- Migraine, Migraine With Aura, Migraine Without Aura, Chronic Migraine
- Trial name
- TACHIS (NCT06409845)
- Testing
- Eptinezumab 100 or 300 mg ev
- Where
- Italy
- Volunteers
- 130 people
- Sponsor
- University of Florence
Episodic Migraine
Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments.
This study will assess the safety, tolerability, and efficacy of Atogepant 60 mg compared with placebo in participants with episodic migraine and who have previously failed 2 to 4 classes of oral prophylactic treatments.
- Trial name
- ELEVATE (NCT04740827)
- Testing
- Atogepant 60 mg
- Where
- 114 sites in United States, Australia and 13 more
- Volunteers
- 315 people
- Sponsor
- Allergan
Migraine
Treximet Trademark (TM) in the Prevention and Modification of Disease Progression in Migraine
This study is being conducted to evaluate the hypothesis that use of pharmacological and non-pharmacological interventions may allow subjects at high risk for chronic migraine to avoid or reverse the transformation of episodic…
- Trial name
- NCT01300546
- Testing
- Sumatriptan/Naproxen Sodium, Naproxen Sodium
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Cady, Roger, M.D.
Migraine, Episodic Migraine
Safety and Tolerability Study of Daily Dosing Rimegepant in Episodic Migraine Prevention
The purpose of this study is to further evaluate the long-term safety and tolerability of daily dosing of rimegepant for the prevention of episodic migraine.
- Conditions
- Migraine, Episodic Migraine, Phonophobia, Photophobia
- Trial name
- NCT05207865
- Testing
- Rimegepant
- Where
- 19 sites in United States
- Volunteers
- 441 people
- Sponsor
- Pfizer
Adolescent Migraine
Evaluation of Efficacy and Safety of add-on Alpha-lipoic Acid on Migraine Prophylaxis in Adolescent Population
Migraine causes a substantial impact on the physical and mental health of a child and it is a major cause for time-off school leading to impaired academic performance.
- Trial name
- NCT04064814
- Testing
- Flunarizine 5mg, Alpha lipoic acid 300mg
- Where
- India
- Volunteers
- 60 people
- Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
Migraine
Mechanism-based Choice of Therapy for Pain: Can Successful Prevention of Migraine be Coupled to a Psychophysical Pain Modulation Profile?
Mechanism-based choice of therapy for pain: Can successful prevention of migraine be coupled to a psychophysical pain modulation profile?
- Trial name
- NCT01161017
- Testing
- Amitriptyline, Topiramate
- Where
- Israel
- Volunteers
- 67 people
- Sponsor
- Rambam Health Care Campus
Migraine
Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine
This study will evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to <12 years) and adolescents (12 to <18 years) with episodic migraine.
- Trial name
- OASIS(EM) (NCT03836040)
- Testing
- Erenumab Dose 1, Erenumab Dose 2, Erenumab Dose 3
- Where
- 11 sites in United States, Belgium and 2 more
- Volunteers
- 457 people
- Sponsor
- Amgen
Migraine
A Study to Learn About the Safety and Effects of Rimegepant to Prevent Migraine in Chinese Subjects.
The purpose of this study is to learn about the effects of Rimegepant to help prevent migraine. This study is seeking for participants who: Are male and female of 18 years of age or older.
- Trial name
- NCT05810038
- Testing
- Rimegepant
- Where
- 49 sites in China
- Volunteers
- 787 people
- Sponsor
- Pfizer